logo
  

Performance Food Group Guides Q4 Net Sales Below View; Trims FY24 Net Sales Outlook - Update

While reporting financial results for the third quarter on Wednesday, Performance Food Group Co. (PFGC) provided net sales guidance for the fourth quarter, below estimates. The company also trimmed its net sales guidance for the full-year 2024.

For the fourth quarter, PFG expects net sales in a range of $15.0 billion to $15.4 billion. On average, 11 analysts polled by Thomson Reuters expect the company to report revenues of $15.60 billion for the quarter.

Looking ahead to fiscal 2024, PFG now projects net sales in a range of about $58.1 billion to $58.5 billion, down from the prior expectation of a $59 billion to $60 billion range. The Street is looking for net sales of $59.02 billion for the year.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit. While reporting financial results for the first quarter on Wednesday, off-price retailer TJX Companies, Inc. (TJX) provided its earnings and comparable store sales outlook for the second quarter and raised earnings outlook for the full-year 2024. For the second quarter, the company now expects earnings... Target Corp. shares were losing more than 8 percent in pre-market activity on the NYSE after the general merchandise retailer reported weak profit, sales and comparable sales in its first quarter. Earnings per share missed the Street estimates. Further, the company issued second-quarter outlook and maintained fiscal 2024 forecast.

In this week's video, we highlight Roche's pioneering approach for weight loss and glucose control. Meanwhile, the EMA has taken strict action on certain preterm birth drugs and Bayer has downsized its staff. In a breakthrough for cancer treatment, the FDA has approved a groundbreaking T-cell engager therapy. Amid progress, setbacks emerge as another ALS drug study has faltered, following closely on the heels of Amylyx Pharma's recent decision to withdraw its FDA-approved ALS drug, Relyvrio.

View More Videos
Follow RTT